NCT02794870View on ClinicalTrials.gov

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

July 7, 2017

Study Completion Date

July 7, 2017

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV LID ΔM2-2 1030s vaccine

10\^5.0 PFU; administered as nose drops

BIOLOGICAL

Placebo

Isotonic diluent, administered as nose drops

Trial Locations (8)

10461

Jacobi Med. Ctr. Bronx NICHD CRS, The Bronx

21205

Johns Hopkins University Center for Immunization Research, Baltimore

60612

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago

80045

Univ. of Colorado Denver NICHD CRS, Aurora

90089

Usc La Nichd Crs, Los Angeles

92093-0672

University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla

60614-3393

Lurie Children's Hospital of Chicago (LCH) CRS, Chicago

11794-8111

SUNY Stony Brook NICHD CRS, Stony Brook

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02794870 - Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age | Biotech Hunter | Biotech Hunter